Key features and details
- Mouse monoclonal [8E8] to Human Polyoma virus JCV capsid protein VP1
- Suitable for: Indirect ELISA, WB
- Isotype: IgG2a
Product nameAnti-Human Polyoma virus JCV capsid protein VP1 antibody [8E8]
DescriptionMouse monoclonal [8E8] to Human Polyoma virus JCV capsid protein VP1
Tested applicationsSuitable for: Indirect ELISA, WBmore details
Species reactivityReacts with: Other species
Recombinant full length protein corresponding to Human Polyoma virus JCV capsid protein VP1. Recombinant full length purified major capsid protein VP1 of human polyomavirus JCV expressed in yeast S.cerevisiae.
This product was changed from ascites to tissue culture supernatant on 28/11/2017. Lot numbers higher than GR48370-3, GR185137-5, GR185137-7 and GR185137-8 will be from tissue culture supernatant. Please note that the dilutions may need to be adjusted accordingly.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.2
Preservative: 0.1% Sodium azide
Concentration information loading...
PurityProtein A purified
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab34756 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/1000 - 1/10000.
1/1000 - 1/5000.
1/1000 - 1/10000.
1/1000 - 1/5000.
RelevanceThe human polyomavirus JC virus (JCV) infects greater than 80% of the human population. The JC virus is a small (38-40 nm in diameter) double stranded, circular DNA virus covered by an icosahedral capsid. Infection with JCV is asymptomatic and it occurs in early childhood. After the primary infection, the virus remains in latent state in the kidney, until it's reactivation under immunosuppressive conditions to result in Progressive Multifocal Leukoencephalopathy (PML), a fatal demyelinating disease. 70% of all HIV-1- infected patients will exhibit neurological disorders and between 5 and 8% of all HIV-1-infected patients will develop PML. Similar to other polyomaviruses, JCV can cause tumors when intracerebrally inoculated at high titers into developing rodent. Several reports suggest the association of viruses, especially of the polyomavirus family with different types of human brain tumors. Tumorigenecity of JCV is most likely induced by the viral early gene product T-antigen. T-antigen has the capacity to interact with several tumor suppressor proteins, most notably p53, and functionally inactivate these proteins.
- Entrez Gene: 2828425 Other species
ab34756 has been referenced in 10 publications.
- Scribano S et al. Archetype JC polyomavirus DNA associated with extracellular vesicles circulates in human plasma samples. J Clin Virol 128:104435 (2020). PubMed: 32442760
- Wilczek MP et al. JC Polyomavirus Infection Reveals Delayed Progression of the Infectious Cycle in Normal Human Astrocytes. J Virol 94:N/A (2020). PubMed: 31826993
- Reoma LB et al. Fatal encephalopathy with wild-type JC virus and ruxolitinib therapy. Ann Neurol 86:878-884 (2019). PubMed: 31600832
- DuShane JK et al. High-Throughput Characterization of Viral and Cellular Protein Expression Patterns During JC Polyomavirus Infection. Front Microbiol 10:783 (2019). PubMed: 31065251
- Diotti RA et al. Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab. Viruses 8:N/A (2016). PubMed: 27164128
- Nukuzuma S et al. Suppressive effect of topoisomerase inhibitors on JC polyomavirus propagation in human neuroblastoma cells. Microbiol Immunol 60:253-60 (2016). ICC . PubMed: 26935240
- Sharma BN et al. Antiviral effects of artesunate on JC polyomavirus replication in COS-7 cells. Antimicrob Agents Chemother 58:6724-34 (2014). ICC/IF . PubMed: 25155602
- Henriksen S et al. The human fetal glial cell line SVG p12 contains infectious BK polyomavirus. J Virol 88:7556-68 (2014). PubMed: 24760884
- Diotti RA et al. Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy. Antiviral Res 108:94-103 (2014). WB . PubMed: 24909571
- Lin J et al. Cerebrospinal fluid and serum JC virus antibody detection in multiple sclerosis patients treated with natalizumab. J Neuroimmunol 261:123-8 (2013). ELISA . PubMed: 23800458